Germ cell tumors have been treated with cisplatin-based chemotherapy since the 1970s. While approximately 80% of patients respond well to cisplatin, the remaining 20% do not.For those patients, treatment options are limited, and when the cancer returns after second- and third-line treatments, cancer-related mortality is over 90%. 

Read More